TMU Taipei Cancer Center

Precision Medicine in Cancer

Tri-Service General Hospital

TTY Biopharm Company Limited

TTY is committed to building itself as a biotech pharmaceutical company advanced in drug development and international marketing. On one hand, TTY is continuously improving its ability to gear to international developments in areas such as international technical documentation formats (CMC, CTD), execution of international clinical trials, and manufacturing process which matches EMEA and FDA specifications. On the other hand, TTY continues to carefully select the most suitable collaborative partners for new drug development around the world and various target markets. Other than continuing operation in the core channels (medical centers, regional hospitals, district hospitals with development potentials) in Taiwan, TTY will enter the international market through developing high barrier and concept-proved new drugs and biologics with innovative formulations. Presently, TTY has been successful in introducing its own R&D products to regions including EU, Asian Pacific, Middle East regions, Africa, and South America, and has become the best partner for companies which are strong in drug marketing. In the future, TTY will continue its cultivation of Asian target markets (home market) to build up its local strength to become the best partner with the best drug development and marketing capabilities for international innovation and biotech companies in Chinese market. TTY expects to put in low-level investment in developing drugs, biological agents, and innovative drugs of brand new ingredients, highly competitive barrier, and high economic values.

Tungs' Taichung MetroHarbor Hospital

1. FORMOSA SOS
2. Da Vinci Surgical System